Cargando…

Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?

Recombinant tissue plasminogen activator (rTPA) is one of the main portions of acute ischemic stroke management, but unfortunately has some complications. Myocardial infarction (MI) is a hazardous complication of administration of intravenous rTPA that has been reported recently. A 78-year-old lady...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almasi, Mostafa, Razmeh, Saeed, Habibi, Amir Hassan, Rezaee, Amir Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935817/ https://www.ncbi.nlm.nih.gov/pubmed/27441068 http://dx.doi.org/10.4081/ni.2016.6617

Ejemplares similares

Pantothenate kinase-associated neurodegeneration: Clinical aspects, diagnosis and treatments
por: Razmeh, Saeed, et al.
Publicado: (2018)

Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger
por: Sweta, Adatia, et al.
Publicado: (2010)

Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Choi, Joon-Ho, et al.
Publicado: (2016)

Treatment of Levodopainduced dyskinesia with Vitamin D: A Randomized, double-blind, placebo-controlled trial
por: Habibi, Amir Hassan, et al.
Publicado: (2018)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Stiff person case misdiagnosed as conversion disorder: A case report
por: Razmeh, Saeed, et al.
Publicado: (2017)

Kounis syndrome presenting with acute inferior wall myocardial infarction and cardiogenic shock secondary to intravenous ampicillin/sulbactam administration
por: Keskin, Muhammed, et al.
Publicado: (2016)

Characteristics of blood tests in patients with acute cerebral infarction who developed symptomatic intracranial hemorrhage after intravenous administration of recombinant tissue plasminogen activator
por: Lee, Chungjo, et al.
Publicado: (2019)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
por: Chapman, Sherita N, et al.
Publicado: (2014)

Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment
por: Deguchi, Ichiro, et al.
Publicado: (2016)

Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy
por: Shibata, Soichiro, et al.
Publicado: (2022)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2011)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration After Acute Ischemic Stroke
por: Jiang, Run-Hao, et al.
Publicado: (2019)

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer
por: Yoneda, Yukihiro, et al.
Publicado: (2014)

Differences between predictive factors for early neurological deterioration due to hemorrhagic and ischemic insults following intravenous recombinant tissue plasminogen activator
por: Tanaka, Koji, et al.
Publicado: (2019)

Thrombolysis in Inferior Myocardial Infarct – Unhelpful?
por: D’Costa, D F
Publicado: (1999)

Acute Myocardial Infarction following Naltrexone Consumption; a Case Report
por: Dadpour, Bita, et al.
Publicado: (2017)

Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis
por: HIRANO, Teruyuki
Publicado: (2015)

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator
por: Liu, Shi-Ying, et al.
Publicado: (2018)

Coronary aspiration thrombectomy after using intravenous recombinant tissue plasminogen activator in a patient with acute ischemic stroke: a case report
por: Mai Duy, Ton, et al.
Publicado: (2019)

Acute Myocardial Infarction Due to Stent Thrombosis After Administration of Intravenous Epinephrine for Anaphylaxis
por: Park, Jung Soo, et al.
Publicado: (2015)

Frequency of Right Ventricular Infarction in Inferior Wall Myocardial Infarction
por: Ali, Hassam, et al.
Publicado: (2020)

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
por: Ohtani, Toshiyuki, et al.
Publicado: (2019)

Association of Geographical Factors With Administration of Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Kunisawa, Susumu, et al.
Publicado: (2013)

When is the best time to mobilize patients after myocardial infarction? An issue that merits further research
por: Sharifi, Hassan, et al.
Publicado: (2016)

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers
por: Aparicio, Hugo J., et al.
Publicado: (2015)

Homocystinuria with Cerebral Venous Sinus Thrombosis: Excellent Recovery with Intravenous Recombinant Tissue Plasminogen Activator
por: Gowda, Vykuntaraju K, et al.
Publicado: (2017)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

A novel homozygous variation in the PANK2 gene in two Persian siblings with atypical pantothenate kinase associated neurodegeneration
por: Habibi, Amir Hasan, et al.
Publicado: (2019)

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator: Erratum
Publicado: (2019)

Intravenous tissue plasminogen activator for ischemic stroke in early pregnancy dosed by actual body weight
por: Peksa, Gary D, et al.
Publicado: (2019)

Mechanical Thrombectomy With and Without Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis Using Nested Knowledge
por: Adusumilli, Gautam, et al.
Publicado: (2021)

THE EFFECT OF A TISSUE PLASMINOGEN ACTIVATOR ON MYOCARDIAL INFARCTION THAT ARE POSITIVE FOR COVID-19
por: Annie, Frank H., et al.
Publicado: (2021)

Therapeutic effect of recombinant tissue plasminogen activator on acute cerebral infarction at different times
por: Liu, Ming, et al.
Publicado: (2013)

The Early Outcomes of Nurse Case Management in Patients with Acute Ischemic Stroke Treated with Intravenous Recombinant Tissue Plasminogen Activator: A Prospective Randomized Controlled Trial
por: Kummarg, Urai, et al.
Publicado: (2018)

Comparison of Effectiveness and Safety of Low-Dose Versus Standard-Dose Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke: A Meta-Analysis
por: Karedath, Jithin, et al.
Publicado: (2023)

Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke
por: Chaucer, Benjamin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_36g5k6kh3huec6v99agc2udgmd